BioVectra Aims to Scale Company with new Board of Director Members

BioVectra, a leading Canadian biotech and pharmaceutical CDMO based in Charlottetown, Prince Edward Island, has appointed two new members to their board of directors.

Gordon C. McCauley, the President and CEO of adMare BioInnovations and Steven Klosk, retired CEO of Cambrex Corporation have joined the BioVectra board.

The growth of the board of directors is in parallel to the company’s ambitious growth plans. BioVectra specializes in clinical-to-commercial scale production capabilities for a range of products including biologics, bioreagents, synthetic and fermented small molecules, and active pharmaceutical ingredients. Working with experts and adding high skill jobs to the island serves to enhance the province’s economy. 

Their expertise in microbial fermentation and chemical synthesis has allowed them to tackle the industry’s increasingly complex molecules. McCauley’s expertise as a life science executive and investor will aid in their plans to scale the company. Klosk has over 25 years of experience in CDMO leadership and will bring industry expert insight.

Who We Are:

Swanson Reed is one of Canada’s largest Specialist SR&ED tax advisory firms. We manage all facets of the SR&ED tax credit program, from claim preparation and audit compliance to claim disputes.

If you would like to find out more about how your business could benefit from R&D Tax Credit, contact a Swanson Reed R&D Tax Advisor today.